Leukemia

CStone Pharmaceuticals on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million worth of the company’s shares in the open market over the next six months.

FAST NEWS: CStone says CEO to boost company holdings

The latest: CStone Pharmaceuticals (2616.HK) on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million ($640,000) worth of the company’s shares in the open market over the…
2616.HK

Recent Articles

RELATED ARTICLES

  1. The share price fell nearly 40% in a week after this drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks.
    Stock disconnect triggers investor exodus from CStone Pharma
    2616.HK
  2. FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
    2616.HK
  3. CHINA BULLETIN: Bring on the Equipment Upgrades, Says Beijing
  4. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  5. HBM gets health boost from drug licensing deals
    2142.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva